Entries by Carme Lopez

SALVAT receives FDA approval for Clotic®, an innovative treatment for otomycosis with Orphan Drug Designation

16/10/2025 in , , /by

This new drug, formulated with clotrimazole as its active pharmaceutical ingredient, addresses a significant unmet clinical need in the management of otomycosis. It offers a highly effective therapeutic option for alleviating the hallmark symptoms of fungal infections affecting the external auditory canal. Following its commercial rollout in Spain in September 2025, it is scheduled for […]

Jordi Muntañola, new CEO of the Salvat Pharmaceutical Group

12/02/2025 in , , /by

A new phase begins for the Salvat Pharmaceutical Group, comprised of Laboratorios Salvat, Pharmaloop, and Salvat USA. The pharmaceutical company has appointed Jordi Muntañola as the new Chief Executive Officer (CEO). With an international leadership profile and over 20 years of experience in the pharmaceutical industry, Muntañola takes on the role with the aim of […]

Salvat becomes the first Spanish pharmaceutical company to receive FDA approval for sterile drug manufacturing using BFS technology

15/10/2024 in , , /by

The pharmaceutical company Salvat has received FDA approval to manufacture Otovel, an ear drop solution for the treatment of acute otitis media, at its Pharmaloop facility in Alcalá de Henares for distribution in the U.S. market. In addition to Otovel, Salvat is expected to produce three more products from its otolaryngology and ophthalmology lines for […]

Laboratorios Salvat strengthens its commitment to those affected by glaucoma by meeting their specific needs

12/03/2024 in , , , /by

The pharmaceutical company and the Glaucoma Association for People Affected and Families (AGAF) in collaboration and endorsed by the Spanish Glaucoma Society will publish the book ‘The 101 doubts about Glaucoma that you always wanted to know and did not dare to ask’. The laboratory thus reaffirms its presence in the field of ophthalmology to […]

Salvat Laboratories initiates a pioneering pediatric study in Europe with its innovative drug SVT-15473, for the treatment of inflammation and pain following ocular surgery

07/07/2023 in , , /by

Phase III clinical trials conducted in adults confirm the efficacy and excellent safety profile of SVT-15473 ophthalmic clobetasol, formulated with IMPACT-SVT® patented nanoemulsion technology, for the treatment of inflammation and pain following ocular surgery. This is the first clinical study conducted in Europe in pediatric patients with a topical ophthalmic corticosteroid. With the new study, […]

Salvat Laboratories presented Phase III clinical trials results of Clobetasol Nanoemulsion for treating inflammation and pain after ocular surgery at the 2023 ARVO Annual Meeting

24/05/2023 in , , /by

Salvat Laboratories, the international pharmaceutical company focused on the development, manufacturing, and commercialization of ophthalmology treatments, announced the results of phase III clinical trials of its most potent ophthalmic corticosteroid in the global ophthalmology market at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting held from 23-27 April 2023 in New Orleans. […]

Salvat Laboratory submits application to the U.S. FDA for approval of Clotrimazole, a pioneering drug for the treatment of otomycosis

01/12/2022 in , , /by

The new drug will be the only one on the market in the United States and Europe specifically formulated and indicated for the topical treatment of fungal otitis externa. Salvat has invested 22 million euros in this project with which reinforces its position as a leading laboratory in the field of otology at an international […]

Salvat Laboratories announces submission of New Drug Application to the U.S. FDA for Clobetasol Nanoemulsion for treating inflammation and pain after ocular surgery

25/10/2022 in , , /by

Salvat Laboratories, the international company which developed and owns the globally commercialized products Otovel and Cetraxal, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of the first ocular corticosteroid formulated in a nanoemulsion for inflammation and pain in post-ocular surgery patients. […]

Salvat, pioneer in using cell-therapy for the treatment of non-consolidated bone fractures (BONECURE project)

07/09/2022 in , , /by

It is an innovative project based on pre-differentiated mesenchymal stem cells designed to treat patients with bone consolidation problems post-fracture (atrophic pseudoarthrosis). A Phase II clinical trial has been completed, with very promising results in terms of efficacy and safety, in patients with pseudoarthrosis of long bones. Salvat has invested more than 10 million Euros […]